Physician profile
Phillip Levine
NPI 1477578805
$584.79
in general payments reported to CMS, 2019-2025
16 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $11.53 · 2022: $18.84 · 2023: $169 · 2024: $67.50 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $85.92 | 2019-2023 | Repatha |
| Edwards Lifesciences Corporation | $72.20 | 2023-2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $51.59 | 2024-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $49.42 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $44.53 | 2019 | |
| Abbott Laboratories | $42.27 | 2023-2024 | Aveir |
| Sanofi-Aventis U.S. LLC | $33.96 | 2019 | |
| Pfizer INC. | $28.24 | 2023 | |
| Boston Scientific Corporation | $28.15 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.45 | 2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $25.34 | 2024 | Verquvo |
| Amarin Pharma, INC. | $24.31 | 2019 | |
| Lilly USA, LLC | $22.15 | 2025 | Zepbound, Mounjaro |
| Bridgebio Pharma, INC. | $17.75 | 2025 | Attruby |
| Medtronic Vascular, INC. | $17.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15.51 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.